Kate Haviland: So that’s unaided awareness. So I think that’s unusual at this point and this early in a prelaunch phase to have that level of awareness. And so I think – I also think it’s important, as Philina had mentioned before, our data analytic capability is critical here. This is not a reach and frequency model. This is about getting to health care providers at a time when it’s most relevant to them, meaning they’ve seen a patient recently. And so that is something again, that we have really worked hard on and the team has done an incredible job through the advanced SM launch, getting that model up and running.
Reni Benjamin: Great. Thank you.
Operator: Our next question comes from Joe Beatty from Baird. Your line is now open.
Joe Beatty: Great. Thank you. How is the current payer coverage for ISM? And are you able to help frame what approval rate you’ve been seeing by this for ISM?
Kate Haviland: Thanks for that question. I think I’ll fit to Philina, but I have to say that market access has been an incredible strength of our launches to date and we are very well positioned moving into the ISM launch. Do you want to talk more about that, Philina?
Philina Lee: Yeah and so to be clear, ISM is just a small fraction of our current business today and coverage and access are strong across the full spectrum of SM patients. There’s just one broad SM code and so payers aren’t necessarily able to distinguish the difference between advanced SM and ISM today. And as we’ve talked about previously, we have exceptionally strong payer coverage with virtually no access challenges.
Joe Beatty: Thank you.
Operator: Our next question comes from Peter Lawson from Barclays. Please go ahead.
Peter Lawson: Thanks. Maybe a question for Becker just on getting to a recommended Phase 2 dose with your CDK2 inhibitor or if that’s a moot point because you’ve kind of have the ability to start the combination regimen. Just so any sense whether we should see that recommended Phase 2 dose in the first half or if we should be kind of waiting until you’re off partial clinical hold?
Becker Hewes: Yeah, I mean, so first of all, as Kate mentioned, the FDA time line is the FDA time line. We don’t have control over that, but we are encouraged by how quickly we are working with them. I think that both the recommended Phase 2 dose and the combination dose are important because this is potentially very broad program that involves a number of tumor types. The combination is relevant for breast cancer, but CDK2 is really central to the biology of quite a few different tumor types and different biology. So with respect to – we’ve gone really quickly through dose escalation. And so in terms of – it’s really not just is recommended Phase 2 dose, it’s a range of activity where we have a good safety profile. And I already think we have that in sight.
So I think that the data that we are able to present midyear will provide a clear view of where we’re going both with single agent and then very early data on the combination. They’ll need more time to escalate more deeply into that ribociclib combination. It’s also important to realize that we can start the chemotherapy combination as well in the near future after we come off of the partial clinical hold. So I think it’s important to focus not just on that one dose but also on the holistic program.
Peter Lawson: Is this captured under Project Optimus as well?
